Research results have been released stating that a new mRNA vaccine has been developed that can treat glioblastoma.
The research results, published in Cell, suggest a new mRNA cancer vaccine to treat glioblastoma by strengthening the patient’s immune system.
Glioblastoma is the most common type of brain cancer, affecting approximately 3 out of every 100,000 people worldwide each year. Since the tumor develops in the brain, getting treatment is difficult. The average five-year survival rate for patients with glioblastoma is known to be 6.9%.
According to recent research, the incidence of glioblastoma is steadily increasing due to environmental factors such as aging populations and air pollution.
mRNA vaccines are differentiated from other traditional protein-centered vaccines as they utilize the genetic code in mRNA that stores information about proteins. After active research and development of mRNA vaccines during the COVID-19 pandemic, scientists have been studying their use in other diseases, including cancer.
The researchers evaluated the effects of the mRNA vaccine through animal experiments before clinical trials. The dogs vaccinated with the vaccine survived an average of 139 days, compared to the control group, which survived approximately 30 to 60 days.
The research team received FDA approval for a small-scale clinical trial involving four participants suffering from glioblastoma and expanded the study.
The experts observed an increase in immune system activity within 48 hours after vaccination.
The study team emphasized that this small-scale clinical trial proved early safety and feasibility for expanding to larger clinical trials, and preparations should be made for a phase 2 clinical trial involving a larger patient group.
Most Commented